Endotoxin-neutralizing activity of hen egg phosvitin

Molecular Immunology

Volumn 53, Issue 4, 2013, Pages 355-362

  Ma, Jie ^a   Wang, Hongmiao ^a   Wang, Yongjun ^b   Zhang, Shicui ^a  

^a OCEAN UNIVERSITY OF CHINA   (China)

^b NANTONG UNIVERSITY   (China)

Author keywords

Antimicrobial activity; Endotoxin; Lipopolysaccharide (LPS); Phosvitin (Pv); Sepsis; Tumor necrosis factor (TNF)

Indexed keywords

ENDOTOXIN; LIPOPOLYSACCHARIDE; LIPOTEICHOIC ACID; PEPTIDOGLYCAN; PHOSVITIN; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL CELL; ANTIMICROBIAL ACTIVITY; ARTICLE; EGG; EGG YOLK; ENDOTOXEMIA; ESCHERICHIA COLI; FEMALE; HEN; MACROPHAGE; NONHUMAN; PRIORITY JOURNAL; STAPHYLOCOCCUS AUREUS; SURVIVAL RATE; TEMPERATURE STRESS;

ANIMALS; ANTI-INFLAMMATORY AGENTS; CELL LINE; ENDOTOXEMIA; ERYTHROCYTES; ESCHERICHIA COLI; FEMALE; HUMANS; LIPOPOLYSACCHARIDES; MACROPHAGES; MALE; MICE; PHOSVITIN; SEPSIS; STAPHYLOCOCCUS AUREUS; SURVIVAL RATE; TUMOR NECROSIS FACTOR-ALPHA;

DANIO RERIO; ESCHERICHIA COLI; MURINAE; MUS; STAPHYLOCOCCUS AUREUS;

EID: 84867379851     PISSN: 01615890     EISSN: 18729142     Source Type: Journal    
DOI: 10.1016/j.molimm.2012.09.006     Document Type: Article

References (30)

1. Abe Y., Itoh T., Adachi S. Fractionation and characterization of hen's egg yolk phosvitin. Journal of Food Science 1982, 47:1903-1907.
2. Beutler B., Cerami A. Cachectin/tumor necrosis factor: an endogenous mediator of shock and inflammation. Immunologic Research 1986, 5:281-293.
3. Bone R.C. The pathogenesis of sepsis. Annals of Internal Medicine 1991, 115:457-469.
4. Bone R.C., Balk R.A., Fein A.M., Perl T.M., Wenzel R.P., Reines H.D., Quenzer R.W., Iberti T.J., Macintyre N., Schein R.M. A second large controlled clinical study of E5, a monoclonal antibody to endotoxin: results of a prospective, multicenter, randomized, controlled trial. Critical Care Medicine 1995, 23:994-1006.
5. Bulet P., Stocklin R., Menin L. Anti-microbial peptides: from invertebrates to vertebrates. Immunological Reviews 2004, 198:169-184.
6. Evans G.F., Snyder Y.M., Butler L.D., Zuckerman S.H. Differential expression of interleukin-1 and tumor necrosis factor in murine septic shock models. Circulatory Shock 1989, 29:279-290.
7. Ghiselli R., Giacometti A., Cirioni O., Circo R., Mocchegiani F., Skerlavaj B., D'Amato G., Scalise G., Zanetti M., Saba V. Neutralization of endotoxin in vitro and in vivo by Bac7(1-35), a proline-rich antibacterial peptide. Shock 2003, 19:577-581.
8. Giacometti A., Cirioni O., Ghiselli R., Viticchi C., Mocchegiani F., Riva A., Saba V., Scalise G. Effect of mono-dose intraperitoneal cecropins in experimental septic shock. Critical Care Medicine 2001, 29:1666-1669.
9. Guérin-Dubiard C., Anton M., Dhene-Garcia A., Martinet V., Brulé G. Hen egg and fish egg phosvitins: composition and iron binding properties. European Food Research and Technology 2002, 214:460-464.
10. Hack C.E., Aarden L.A., Thijs L.G. Role of cytokines in sepsis. Advances in Immunology 1997, 66:101-195.
11. Hancock R.E. Cationic peptides: effectors in innate immunity and novel antimicrobials. Lancet Infectious Diseases 2001, 1:156-164.
12. Hegenauer J., Ripley L., Nace G. Staining acidic phosphoproteins (phosvitin) in electrophoretic gels. Analytical Biochemistry 1977, 78:308-311.
13. Khan M.A.S., Nakamura S., Ogawa M., Akita E., Azakami H., Kato A. Bactericidal action of egg yolk phosvitin against Escherichia coli under thermal stress. Journal of Agricultural and Food Chemistry 2000, 48:1503-1506.
14. Leaver S.K., Finney S.J., Burke-Gaffney A., Evans T.W. Sepsis since the discovery of Toll-like receptors: disease concepts and therapeutic opportunities. Critical Care Medicine 2007, 35:1404-1410.
15. Li Z., Zhang S., Liu Q. Vitellogenin functions as a multivalent pattern recognition receptor with an opsonic activity. PLoS One 2008, 3:e1940.
16. Mayumi T., Takezawa J., Takahashi H., Kuwayama N., Fukuoka T., Shimizu K., Yamada K., Kondo S., Aono K. Low-dose intramuscular polymyxin B improves survival of septic rats. Shock 1999, 11:82-86.
17. Mookherjee N., Hancock R.E. Cationic host defence peptides: innate immune regulatory peptides as a novel approach for treating infections. Cellular and Molecular Life Sciences 2007, 64:922-933.
18. Parrillo J.E. Pathogenetic mechanisms of septic shock. New England Journal of Medicine 1993, 328:1471-1477.
19. Ren J., Gao H., Tang M., Gu J., Xia P., Xiao G. Lipopolysaccharide (LPS) detoxification of analogue peptides derived from limulus anti-LPS factor. Peptides 2010, 31:1853-1859.
20. Ren J.D., Gu J.S., Gao H.F., Xia P.Y., Xiao G.X. A synthetic cyclic peptide derived from Limulus anti-lipopolysaccharide factor neutralizes endotoxin in vitro and in vivo. International Immunopharmacology 2008, 8:775-781.
21. Rice T.W., Bernard G.R. Therapeutic intervention and targets for sepsis. Annual Review of Medicine 2005, 56:225-248.
22. Rosenfeld Y., Papo N., Shai Y. Endotoxin (lipopolysaccharide) neutralization by innate immunity host-defense peptides. Peptide properties and plausible modes of action. Journal of Biological Chemistry 2006, 281:1636-1643.
23. Russell J.A. Management of sepsis. New England Journal of Medicine 2006, 355:1699-1713.
24. Villa P., Ghezzi P. Animal models of endotoxic shock. Methods in Molecular Medicine 2004, 98:199-206.
25. Wallace R.A., Morgan J.P. Chromatographic resolution of chicken phosvitin. Multiple macromolecular species in a classic vitellogenin-derived phosphoprotein. Biochemical Journal 1986, 240:871.
26. Wang S., Wang Y., Ma J., Ding Y., Zhang S. Phosvitin plays a critical role in the immunity of zebrafish embryos via acting as a pattern recognition receptor and an antimicrobial effector. Journal of Biological Chemistry 2011, 286:22653-22664.
27. Warren H.S. Strategies for the treatment of sepsis. New England Journal of Medicine 1997, 336:952-953.
28. Weiss C.A., Wasiluk K.R., Kellogg T.A., Dunn D.L. Bactericidal and endotoxin neutralizing activity of a peptide derived from Limulus antilipopolysaccharide factor. Surgery 2000, 128:339-344.
29. Zhang G., Ghosh S. Molecular mechanisms of NF-κB activation induced by bacterial lipopolysaccharide through Toll-like receptors. Journal of Endotoxin Research 2000, 6:453-457.
30. Ziegler E.J., Fisher C.J., Sprung C.L., Straube R.C., Sadoff J.C., Foulke G.E., Wortel C.H., Fink M.P., Dellinger R.P., Teng N.N., et al. Treatment of gram-negative bacteremia and septic shock with HA-1A human monoclonal antibody against endotoxin. A randomized, double-blind, placebo-controlled trial. New England Journal of Medicine 1991, 324:429-436.